TRDA·Nasdaq·US
Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines that engage intracellular targets long considered inaccessible. It uses proprietary, versatile and modular approaches to advance a portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others.
Source: SEC 10-K Feb 26, 2026
Recent Activity
Updated Oct 24, 2026
–Entrada Therapeutics reported that Cohort 1 of the Phase 1/2 ELEVATE-45-201 study of ENTR-601-45 in participants with Duchenne muscular dystrophy met its primary objectives of favorable safety and tolerability at the initial 5 mg/kg dose.
–An independent Safety Data Monitoring Committee recommended initiating Cohort 3 at the top dose of 18 mg/kg in Entrada's ELEVATE-44-201 study.
–Entrada expects to receive ELEVATE-44-201 Cohort 1 open-label period data by year-end 2026, and Cohort 2 enrollment in the study is complete.
–Entrada appointed Linea Aspesi as Chief People Officer to help scale its people and organization for its next phase of growth.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.